SPS 10.03(2)(k)4. 4. Homatropine.

SPS 10.03(2)(k)5. 5. Homatropine hydrogen bromide.

SPS 10.03(2)(k)6. 6. Scopolamine.

SPS 10.03(2)(k)7. 7. Tropicamide.

SPS 10.03(2)(L) (L) Antiglaucomatous agents.

SPS 10.03(2)(L)1. 1. Sympathomimetics.

SPS 10.03(2)(L)1.a. a. Dipivefrin.

SPS 10.03(2)(L)1.b. b. Epinephrine.

SPS 10.03(2)(L)2. 2. Miotics, direct acting.

SPS 10.03(2)(L)2.a. a. Acetylcholine.

SPS 10.03(2)(L)2.b. b. Carbachol.

SPS 10.03(2)(L)2.c. c. Pilocarpine.

SPS 10.03(2)(L)3. 3. Miotics, cholinesterase inhibitors.

SPS 10.03(2)(L)3.a. a. Demecarium bromide.

SPS 10.03(2)(L)3.b. b. Echothiophate.

SPS 10.03(2)(L)3.c. c. Isoflurophate.

SPS 10.03(2)(L)3.d. d. Physostigmine.

SPS 10.03(2)(L)4. 4. Topical beta-adrenergic blocking agents.

SPS 10.03(2)(L)4.a. a. Betaxolol.

SPS 10.03(2)(L)4.b. b. Carteolol HCl.

SPS 10.03(2)(L)4.c. c. Levobunolol.

SPS 10.03(2)(L)4.d. d. Metipranolol HCl.

SPS 10.03(2)(L)4.e. e. Timolol.

SPS 10.03(2)(L)5. 5. Oral carbonic anhydrase inhibitors.

SPS 10.03(2)(L)5.a. a. Acetazolamide.

SPS 10.03(2)(L)5.b. b. Dichlorphenamide.

SPS 10.03(2)(L)5.c. c. Methazolamide.

SPS 10.03(2)(m) (m) Any drug or device that is used for an ophthalmic therapeutic purpose and that is the subject of a new drug application approved by the food and drug administration under section 505 (c) (1) of the federal food, drug and cosmetic act, 21 USC 355, as amended.

SPS 10.03(2)(n) (n) Any drug or device that is used for an ophthalmic therapeutic purpose and that is generally exempt from the new drug application approval requirement contained in section 505 of the federal food, drug and cosmetic act, 21 USC 355, as amended.